Panacea Bio Chem's triple-agonist programme: the design and synthesis of unimolecular peptides that engage the GLP-1, GIP and glucagon receptors at once — and of next-generation multi-agonists that reach beyond that canonical trio. Design and synthesis happen inside SYNTHESERACT, Panacea's adaptive continuous-flow synthesis platform.
A single engineered peptide built to activate three related hormone receptors at once: the GLP-1 receptor, the GIP receptor and the glucagon receptor. Because the three natural hormones are structural cousins in the secretin–glucagon superfamily, one chain can be shaped to fit all three locks. The best-known molecule in this class is Eli Lilly's retatrutide, which reported phase-2 results in the New England Journal of Medicine in 2023.
The consensus is the canonical trio: GLP-1 plus GIP plus glucagon, at one fixed balance. Beyond the consensus means treating that trio as a starting point — exploring additional receptor axes alongside it, tuning the potency ratio between arms as a design variable in its own right, and building chemotypes the canonical scaffold does not reach. Panacea publishes the ambition, not the recipes. The full argument is on The Story page.
Panacea Bio Chem's adaptive peptide synthesis platform: continuous-flow solid-phase peptide synthesis (CFSPPS) through modular resin-bed reactors, under continuous process sensing, with residue-event memory — chemistry in motion, synthesis under observation, manufacturing that learns. It is where TRIAGON molecules are designed and made — more at syntheseract.com.
No. TRIAGON is a research programme, not a product, and this site is a showcase of capability and direction — not a catalogue, not a datasheet and not an offer of sale.
By design. TRIAGON's sequences, potency ratios, chemotype choices and results are proprietary and are disclosed through Panacea's official channels when the work can carry its own name. The site shows direction and machinery — the ambition and the platform — and stops where competitive substance begins.
Panacea Bio Chem Ltd, the molecular-performance company behind the SYNTHESERACT synthesis platform, the S3Pulse process engine and the peptide-preservation line (Cryolapse, TgShift, RedoxVault), led by its founder — a biochemist and amino-acid-chain designer.
No. Everything on triagon.uk is research and technology information for scientific context. Nothing here is medical advice, and no peptide described anywhere on this site is offered for sale.